


In the Claims:

Please Cancel claims 13-15 and 17-18

Please Amend Claims 1-12 and 16 as follows.

1. (Currently Amended) A compound of formula (I)



wherein

~~R represents~~ is halogen or C<sub>1-4</sub> alkyl;

~~R<sub>1</sub> represents~~ is hydrogen or C<sub>1-4</sub> alkyl;

~~R<sub>2</sub> represents~~ is hydrogen, C<sub>1-4</sub> alkyl;

~~R<sub>3</sub> represents~~ is hydrogen, C<sub>1-4</sub> alkyl;

~~R<sub>4</sub> represents~~ is trifluoromethyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, trifluoromethoxy or halogen;

~~R<sub>5</sub> represents~~ is hydrogen, C<sub>1-4</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C(O)R<sub>6</sub> or S(O)<sub>2</sub>R<sub>6</sub>;

~~R<sub>6</sub> represents~~ is C<sub>1-4</sub> alkyl or C<sub>3-7</sub> cycloalkyl;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is an integer from 1 to 2;

X and Y are independently C(O) or CH<sub>2</sub>;

provided that

i) X and Y are not both C(O) and

ii) when X and Y are both CH<sub>2</sub> and p is 1, R<sub>5</sub> is not hydrogen, C<sub>1-4</sub> alkyl or C(O)R<sub>6</sub>;

~~and or a pharmaceutically acceptable salts and solvates~~ salt or solvate thereof.

2. (Currently Amended) A compound as claimed in claim 1 wherein ~~R is a halogen (e.g. fluorine) and/or a C<sub>1-4</sub> alkyl (e.g. methyl) group~~ and m is preferably zero or an integer from 1 to 2.
3. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~ wherein R<sub>1</sub> is a methyl group.
4. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 3~~ wherein R<sub>2</sub> is a hydrogen atom or a methyl group.
5. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 4~~ wherein R<sub>3</sub> is a hydrogen atom or a methyl group.
6. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 5~~ wherein R<sub>4</sub> is a trifluoromethyl group or halogen (i.e chlorine).
7. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 6~~ wherein R<sub>5</sub> is hydrogen, ~~methyl~~, methyl cyclopropyl, C(O)CH<sub>3</sub> or S(O)<sub>2</sub>CH<sub>3</sub>.
8. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 7~~ wherein p is 1.
9. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 8~~ wherein R is at the 2 and/or 4 position in the phenyl ring .
10. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 9~~ wherein n is 2 and the groups R<sub>4</sub> are at the 3 and 5 position in the phenyl ring.

11. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 10~~ wherein

R is fluorine and/or C<sub>1-4</sub> alkyl (~~e.g. methyl~~);

R<sub>1</sub> is a methyl group;

R<sub>2</sub> is a hydrogen atom or a methyl group;

R<sub>3</sub> is a hydrogen atom or a methyl group;

R<sub>4</sub> is trifluoromethyl;

R<sub>5</sub> is hydrogen, methyl, ~~methyl~~, cyclopropyl, C(O)CH<sub>3</sub> or S(O)<sub>2</sub>CH<sub>3</sub>;

m is 1 or 2;

n is 2;

p is 1.

12. (Currently Amended) A compound selected from

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;  
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;  
and pharmaceutically acceptable salts (~~e.g. hydrochloride, methanesulphonate, sulphate, p-toluenesulphonate~~) and solvates thereof.

13-15. (Canceled.)

16. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any claims from 1 to 12~~ in a mixture with one or more pharmaceutically acceptable carriers or excipients.

17. (Canceled.)

18. (Canceled.)

Please add new claims 19-26.

19. (New) A method for the treatment of a condition mediated by a tachykinin in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

20. (New) The method as claimed in claim 19, wherein said tachykinin is substance P.


21. (New) The method as claimed in claim 19, wherein said mammal is man.

22. (New) A method for the treatment of a CNS disorder in a man comprising administering an effective amount of a compound as claimed in claim 1.

23. (New) The method according to claim 22, wherein said CNS disorder is selected from depressive states and anxiety.


24. (New) A method for the treatment of emesis in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

25. (New) A process for preparing a compound according to claim 1, wherein X is CH<sub>2</sub> or C(O) and Y is CH<sub>2</sub>, said process comprising reacting a compound of formula (II):



(II)

with compound of formula (III):




(III)

in the presence of a suitable metal reducing agent;

followed where necessary or desired by one or more of the following steps:

- i) removing any protecting group;
- ii) isolating the compound as a salt or a solvate thereof; or
- iii) separating the compound into enantiomers thereof.

26. (New) A process for preparing a compound according to claim 1, wherein Y is C(O), said process comprising cyclizing a compound of formula (VII),



(VII)

wherein P is a nitrogen protecting group and L is a suitable leaving group;

followed where necessary or desired by one or more of the following steps:

PI4748USw

- i) removing any protecting group;
- ii) isolating the compound as a salt or a solvate thereof;
- iii) separating the compound into enantiomers thereof.